ReviewFrontiers in microbiology2021
Spotlight on the Compositional Quality of Probiotic Formulations Marketed Worldwide.
Review in Frontiers in microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Placebo-resistant gut bacteria:Frontiers in cellular and infection microbiology · 2024Trial
- Safety and Effectiveness of Probiotic Preparations: A Contemporary Review.Diseases (Basel, Switzerland) · 2026Review
- Microbiome Engineering in Dairy Cattle: A Critical Review of Strategies for Disease Resistance, Productivity, and Sustainable Farming.Veterinary sciences · 2026Review
- Exploring the Role of Probiotics in the Prevention and Treatment of Gastrointestinal Cancer.Probiotics and antimicrobial proteins · 2026Review
- Review
- Probiotics and the Human Microbiome: Classical Functions, Emerging Systemic Roles, and Future Therapeutic Frontiers.Biology · 2026Review
- Genesis, Health Benefits, and Future Perspectives of Probiotics: Exploring Endogenous and Exogenous Classes, Innovations, and Research Gaps.Probiotics and antimicrobial proteins · 2026Review
- Informed Therapeutic Microbiome Modulation for Post-Infectious Irritable Bowel Syndrome: Pilot Experience of a Microbiome Clinic.Nutrients · 2026Article
- Evaluating the Quality of Selected Commercial Probiotic Products, Both Dietary Supplements and Foods for Special Medical Purposes.Foods (Basel, Switzerland) · 2026Article
- Managing Gut Dysbiosis: Clinical Evidence and Perspectives onMicroorganisms · 2026Review
- How "pro" are probiotics for wildlife species? Novel data, lack of evidence, and future directions.ISME communications · 2026Article
- Uncovering the Probiotic Supplement Landscape: Market Offerings, Sales Patterns, and Future Forecasts Using Machine Learning Approach - A Case Study of Montenegro.Probiotics and antimicrobial proteins · 2025Article
- Evaluating the Compositional Quality of Probiotics Containing Bacillus clausii in India.Advances in therapy · 2025Article
- Probiotic Spores ofInternational journal of molecular sciences · 2025Article
- Postbiotics in pediatric clinical practice: position paper from Special Group of Latin American Society of Pediatric Gastroenterology, Hepatology and Nutrition (LASPGHAN).Frontiers in nutrition · 2025Article
- Assessing the authenticity and purity of a commercialFrontiers in microbiology · 2025Article
- Progress in Probiotic Science: Prospects of Functional Probiotic-Based Foods and Beverages.International journal of food science · 2025Review
- Probiotics: A multifaceted approach to health promotion-from disease prevention to food enrichment and delivery systems.AIMS microbiology · 2025Review
- Article
- Safety Assessment and Evaluation of Probiotic Potential ofMicroorganisms · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
On the worldwide market, a great number of probiotic formulations are available to consumers as drugs, dietary supplements, and functional foods. For exerting their beneficial effects on host health, these preparations should contain a sufficient amount of the indicated living microbes and be pathogen-free to be safe. Therefore, the contained microbial species and their amount until product expiry are required to be accurately reported on the labels. While commercial formulations licensed as drugs are subjected to rigorous quality controls, less stringent regulations are generally applied to preparations categorized as dietary supplements and functional foods. Many reports indicated that the content of several probiotic formulations does not always correspond to the label claims in terms of microbial identification, number of living organisms, and purity, highlighting the requirement for more stringent quality controls by manufacturers. The main focus of this review is to provide an in-depth overview of the microbiological quality of probiotic formulations commercialized worldwide. Many incongruences in the compositional quality of some probiotic formulations available on the worldwide market were highlighted. Even if manufacturers carry at least some of the responsibility for these inconsistencies, studies that analyze probiotic products should be conducted following recommended and up-to-date methodologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.